Karyopharm Therapeutics(KPTIQ)
$0.020.00 (0.00%)
KPTIQ
Karyopharm Therapeutics financials statements
$0.02
At close:0.00 (0.00%)
Want to see KPTIQ full AI Analyst Report?
Karyopharm Therapeutics (KPTIQ) Ratios
1,274 Followers
Karyopharm Therapeutics Ratios
KPTIQ's free cash flow for Q2 2026 was $-24.93M. For the 2026 fiscal year, KPTIQ's free cash flow was increased by $0.00 and operating cash flow was $-24.93M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.12 | 1.70 | 3.37 | 5.31 | 3.74 |
| Quick Ratio | 1.08 | 1.64 | 3.32 | 5.25 | 3.68 |
| Cash Ratio | 0.66 | 0.68 | 0.75 | 2.05 | 2.58 |
| Solvency Ratio | -0.49 | -0.22 | -0.38 | -0.44 | -0.32 |
| Operating Cash Flow Ratio | -0.82 | -1.38 | -1.33 | -2.27 | -1.45 |
| Short-Term Operating Cash Flow Coverage | -3.59 | -5.22 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -298.20M | $ -193.94M | $ -142.72M | $ -24.67M | $ -109.37M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.15 | 1.18 | 0.74 | 0.50 | 0.59 |
| Debt-to-Equity Ratio | -0.80 | -1.05 | -1.30 | -10.75 | -2.27 |
| Debt-to-Capital Ratio | -3.94 | 22.87 | 4.34 | 1.10 | 1.79 |
| Long-Term Debt-to-Capital Ratio | -2.37 | -7.06 | 4.92 | 1.11 | 1.89 |
| Financial Leverage Ratio | -0.37 | -0.88 | -1.77 | -21.50 | -3.83 |
| Debt Service Coverage Ratio | -2.24 | -0.63 | -4.98 | -5.59 | -3.73 |
| Interest Coverage Ratio | -1.98 | -3.19 | -5.44 | -5.69 | -3.77 |
| Debt to Market Cap | 2.82 | 2.27 | 1.73 | 0.61 | 0.35 |
| Interest Debt Per Share | 25.56 | 28.55 | 26.38 | 37.39 | 41.21 |
| Net Debt to EBITDA | -1.15 | -3.42 | -1.05 | -0.32 | 0.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 95.93% | 95.86% | 96.62% | 96.68% | 98.38% |
| EBIT Margin | -102.79% | -26.81% | -81.46% | -89.08% | -46.60% |
| EBITDA Margin | -102.59% | -26.58% | -81.09% | -88.69% | -46.22% |
| Operating Profit Margin | -62.10% | -82.24% | -88.71% | -90.53% | -46.84% |
| Pretax Profit Margin | -134.18% | -52.58% | -97.77% | -105.00% | -59.01% |
| Net Profit Margin | -134.21% | -52.62% | -97.99% | -105.23% | -59.14% |
| Continuous Operations Profit Margin | -134.21% | -52.62% | -97.99% | -105.23% | -59.14% |
| Net Income Per EBT | 100.02% | 100.07% | 100.23% | 100.22% | 100.22% |
| EBT Per EBIT | 216.08% | 63.93% | 110.22% | 115.98% | 126.00% |
| Return on Assets (ROA) | -180.82% | -46.48% | -59.52% | -46.15% | -40.64% |
| Return on Equity (ROE) | 66.92% | 41.08% | 105.06% | 992.38% | 155.75% |
| Return on Capital Employed (ROCE) | -554.58% | -165.54% | -75.77% | -48.66% | -42.43% |
| Return on Invested Capital (ROIC) | -236.62% | -123.11% | -74.33% | -48.18% | -42.01% |
| Return on Tangible Assets | -180.82% | -46.48% | -59.52% | -46.15% | -40.64% |
| Earnings Yield | -243.58% | -92.77% | -144.78% | -59.38% | -25.70% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.58 | 4.72 | 5.42 | 3.34 | 9.33 |
| Payables Turnover | 1.49 | 1.18 | 1.58 | 1.88 | 2.12 |
| Inventory Turnover | 1.47 | 1.27 | 1.62 | 1.23 | 0.83 |
| Fixed Asset Turnover | 31.40 | 23.11 | 29.91 | 21.29 | 21.95 |
| Asset Turnover | 1.35 | 0.88 | 0.61 | 0.44 | 0.69 |
| Working Capital Turnover Ratio | 3.88 | 1.27 | 0.65 | 0.65 | 1.00 |
| Cash Conversion Cycle | 67.56 | 54.96 | 61.48 | 211.01 | 307.68 |
| Days of Sales Outstanding | 65.41 | 77.32 | 67.39 | 109.42 | 39.14 |
| Days of Inventory Outstanding | 247.75 | 287.95 | 224.75 | 295.75 | 440.53 |
| Days of Payables Outstanding | 245.60 | 310.31 | 230.65 | 194.16 | 171.99 |
| Operating Cycle | 313.17 | 365.27 | 292.14 | 405.17 | 479.67 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -6.89 | -15.69 | -12.18 | -27.40 | -21.36 |
| Free Cash Flow Per Share | -6.89 | -15.71 | -12.18 | -27.42 | -22.50 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -897.79 | 0.00 | -1267.41 | -18.75 |
| Capital Expenditure Coverage Ratio | 0.00 | -897.79 | 0.00 | -1267.41 | -18.75 |
| Operating Cash Flow Coverage Ratio | -0.32 | -0.66 | -0.52 | -0.84 | -0.59 |
| Operating Cash Flow to Sales Ratio | -0.52 | -0.88 | -0.63 | -0.95 | -0.51 |
| Free Cash Flow Yield | -93.65% | -154.93% | -93.81% | -53.77% | -23.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.41 | -1.08 | -0.69 | -1.68 | -3.89 |
| Price-to-Sales (P/S) Ratio | 0.55 | 0.57 | 0.68 | 1.77 | 2.30 |
| Price-to-Book (P/B) Ratio | -0.27 | -0.44 | -0.73 | -16.71 | -6.06 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.07 | -0.65 | -1.07 | -1.86 | -4.28 |
| Price-to-Operating Cash Flow Ratio | -1.07 | -0.65 | -1.07 | -1.86 | -4.51 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.02 | 0.02 | -0.08 | 0.10 |
| Enterprise Value Multiple | -1.69 | -5.55 | -1.89 | -2.31 | -4.88 |
| Enterprise Value | 253.55M | 214.43M | 223.62M | 322.25M | 473.02M |
| EV to EBITDA | -1.69 | -5.55 | -1.89 | -2.31 | -4.88 |
| EV to Sales | 1.74 | 1.48 | 1.53 | 2.05 | 2.25 |
| EV to Free Cash Flow | -3.36 | -1.68 | -2.41 | -2.15 | -4.19 |
| EV to Operating Cash Flow | -3.36 | -1.68 | -2.41 | -2.15 | -4.42 |
| Tangible Book Value Per Share | -26.79 | -22.90 | -17.89 | -3.05 | -15.89 |
| Shareholders’ Equity Per Share | -26.79 | -22.90 | -17.89 | -3.05 | -15.89 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 13.36 | 17.88 | 19.18 | 28.78 | 41.84 |
| Net Income Per Share | -17.93 | -9.41 | -18.79 | -30.28 | -24.75 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.31 | 1.96 | 1.20 | 1.18 | 1.27 |
| Research & Development to Revenue | 0.86 | 0.99 | 0.95 | 0.95 | 0.77 |
| SG&A to Revenue | 0.72 | 0.79 | 0.90 | 0.93 | 0.69 |
| Stock-Based Compensation to Revenue | 0.10 | 0.13 | 0.15 | 0.23 | 0.14 |
| Income Quality | 0.38 | 1.67 | 0.65 | 0.90 | 0.86 |
Currency in USD
